Core Laboratories (CLB) Liabilities and Shareholders Equity (2022 - 2026)

Core Laboratories' Liabilities and Shareholders Equity history runs 5 years deep, the most recent figure standing at $587.7 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity changed 0.25% year-over-year to $587.7 million in Q1 2026; TTM through Mar 2026 was $2.4 billion, a 0.19% change from a year earlier, with the FY2025 full-year figure at $584.0 million, changed 0.19% from the prior year.
• Liabilities and Shareholders Equity improved to $587.7 million in Q1 2026 per CLB's latest filing, from $584.0 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $602.1 million in Q2 2025 and bottomed at $570.2 million in Q3 2022.
• The 5-year median for Liabilities and Shareholders Equity is $589.5 million (2025), against an average of $589.6 million.
• Across the five-year window, Liabilities and Shareholders Equity climbed 4.21% in 2023 and retreated 1.93% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $578.4 million in 2022, then rose by 1.39% to $586.4 million in 2023, then dropped by 0.22% to $585.1 million in 2024, then dropped by 0.19% to $584.0 million in 2025, then rose by 0.64% to $587.7 million in 2026.
• Per Business Quant, the three latest CLB Liabilities and Shareholders Equity figures stand at $587.7 million (Q1 2026), $584.0 million (Q4 2025), and $591.4 million (Q3 2025).